REGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.com

StockNews.com cut shares of REGENXBIO (NASDAQ:RGNX) from a hold rating to a sell rating in a research report released on Thursday.

Several other brokerages have also weighed in on RGNX. Royal Bank of Canada restated an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a research report on Tuesday. Raymond James reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Thursday, October 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.82.

REGENXBIO Stock Performance

Shares of NASDAQ RGNX opened at $7.95 on Thursday. REGENXBIO has a one year low of $6.56 and a one year high of $28.80. The firm has a market capitalization of $393.84 million, a P/E ratio of -1.58 and a beta of 1.28. The company’s fifty day moving average is $8.52 and its two-hundred day moving average is $10.42.

Institutional Investors Weigh In On REGENXBIO

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 2,510 shares during the period. FMR LLC lifted its stake in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the period. nVerses Capital LLC boosted its holdings in shares of REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 3,720 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in REGENXBIO in the third quarter valued at $140,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.